The small interfering RNA (siRNA) market is at the forefront of a new era in medicine, offering a powerful and precise approach to gene silencing that holds immense therapeutic potential for a wide range of diseases. The small interfering RNA (siRNA) market is experiencing significant growth, driven by increasing investment in RNA-based therapeutics, advancements in delivery technologies, and a growing focus on personalized medicine. Valued at USD 3.3 billion in 2025, the market is projected to reach USD 9 billion by 2035, at a CAGR of 10.6%. This growth underscores the transformative power of siRNA in modern drug discovery and development.

siRNA molecules are short, double-stranded RNA sequences that can selectively silence specific genes by degrading their messenger RNA (mRNA). The market is segmented by application, with the therapeutic segment holding the largest share, reflecting the intense focus on developing siRNA-based drugs for genetic disorders, oncology, and other chronic conditions. Research applications are also significant, as siRNA is a crucial tool for studying gene function. The market includes various delivery methods, with liposomes and nanoparticles being dominant, essential for protecting siRNA and ensuring its efficient delivery to target cells.

Key drivers of this market include the increasing prevalence of genetic disorders and the growing investment in RNA therapeutics. Advancements in delivery mechanisms are also a major factor. For a comprehensive understanding of these dynamics, exploring the small interfering RNA (siRNA) market provides essential insights.